Adaptive Biotechnologies Corporation ADPT
29.52 USD -0.42 (-1.40%)
Nov 12, 2026, 2:24 PM EST
28.59 Day range 29.78
12.00 52-week range 32.21
- YTD
- +81.77%
- 1 year
- +103.59%
News
globenewswire.com Adaptive Biotechnologies to Participate in Upcoming Investor Conferences SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the…
zacks.com Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run? Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $32 to $34.
defenseworld.net Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Has Average Target Price of $30.06 Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight research firms that are currently covering the firm,…
benzinga.com Adaptive Biotechnologies Q3 2026 Earnings Call Transcript Adaptive Biotechnologies (NASDAQ:ADPT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com MercadoLibre, Banco Bradesco, Itaú Unibanco And Other Big Stocks Moving Lower In Monday’s Pre-Market Session Brazilian stocks plunged premarket after Lula's reelection, led by XP (-46%), Inter & Co (-34.7%), StoneCo (-33.8%) and MercadoLibre (-14.1%).
benzinga.com TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32 TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.- benzinga.com Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35 Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.
benzinga.com BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34 BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.
benzinga.com Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6…
benzinga.com ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
benzinga.com Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5 Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.
benzinga.com TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28 TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.- benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $22 to $25.
- benzinga.com BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25 BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $24 to $25.
- benzinga.com UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65.886M Estimate Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. This is a 41.18 percent increase over…
benzinga.com Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estimate Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.14) by 78.57 percent. This is a 47.06 percent decrease over…- benzinga.com Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20 Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $18 to $20.
- benzinga.com Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22 Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $21 to $22.
benzinga.com KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares jumped 16.2%. Other big gainers: WEN, ABSI, RUN, CCXI, ENRD, SFTX, ICCM, INMD, DFH.
benzinga.com Adaptive Biotechnologies Business Separation May Unlock Greater Value William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve flexibility and support valuation.- benzinga.com BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and maintains $22 price target.
- benzinga.com Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M) Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announced the pricing of its offering of $300 million aggregate principal amount of 0% convertible senior notes…
benzinga.com Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue growth accelerate.
benzinga.com Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Buster's, Western Digital In Focus (UPDATED) (Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures were mixed on Tuesday, as the Dow Jones rose, while the Nasdaq 100 and S&P 500 declined, following…
benzinga.com Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
benzinga.com Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
benzinga.com John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Buster's and Adaptive Biotechnologies saw after-hours trading dips.
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Earnings Scheduled For February 5, 2026
benzinga.com Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday 
benzinga.com Ross Stores Posts Strong Q3 Results, Joins Enviri, Azenta And Other Big Stocks Moving Higher On Friday 
benzinga.com Earnings Scheduled For November 5, 2025 
benzinga.com United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - benzinga.com Earnings Scheduled For May 1, 2025
benzinga.com Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com Earnings Scheduled For February 11, 2025
- benzinga.com Top 3 Health Care Stocks That May Collapse This Quarter
- benzinga.com Earnings Scheduled For February 14, 2024 Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is projected to report quarterly earnings at $1.65 per share on revenue of $24.62 billion.